1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Chugai Pharmaceutical Co., Ltd
  6. Summary
    4519   JP3519400000

CHUGAI PHARMACEUTICAL CO., LTD

(4519)
  Report
Delayed Japan Exchange  -  02:00 2022-07-06 am EDT
3624.00 JPY   +1.48%
06/29CHUGAI PHARMACEUTICAL CO., LTD : Ex-dividend day for interim dividend
FA
06/27CHUGAI PHARMACEUTICAL : Script (including Q&A)
PU
06/23CHUGAI PHARMACEUTICAL : Presentation
PU
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Japan Exchange
06/30/2022 07/01/2022 07/04/2022 07/05/2022 07/06/2022 Date
3470(c) 3476(c) 3529(c) 3571(c) 3624(c) Last
3 418 100 2 828 500 1 620 600 1 399 000 2 598 000 Volume
-1.64% +0.17% +1.52% +1.19% +1.48% Change
More quotes
Estimated financial data (e)
Sales 2022 1 186 B 8 732 M 8 732 M
Net income 2022 341 B 2 511 M 2 511 M
Net cash position 2022 516 B 3 801 M 3 801 M
P/E ratio 2022 17,5x
Yield 2022 2,15%
Sales 2023 1 034 B 7 612 M 7 612 M
Net income 2023 313 B 2 304 M 2 304 M
Net cash position 2023 759 B 5 591 M 5 591 M
P/E ratio 2023 19,0x
Yield 2023 2,28%
Capitalization 5 960 B 43 889 M 43 889 M
EV / Sales 2022 4,59x
EV / Sales 2023 5,03x
Nbr of Employees 7 664
Free-Float 37,8%
More Financials
Company
Chugai Pharmaceutical Co. Ltd specializes in the research, development, manufacturing and marketing of drugs especially for cancers (40.8% of net sales), bones and joints diseases treatment (18.4%), and kidney diseases (5.9%). Net sales are distributed geographically as follows: Japan (74,3%), Switzerland (22,8%) and other (2,9%). 
Sector
Pharmaceuticals
Calendar
07/21 | 04:00amEarnings Release
More about the company
Ratings of Chugai Pharmaceutical Co., Ltd
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B+
More Ratings
All news about CHUGAI PHARMACEUTICAL CO., LTD
06/29CHUGAI PHARMACEUTICAL CO., LTD : Ex-dividend day for interim dividend
FA
06/27CHUGAI PHARMACEUTICAL : Script (including Q&A)
PU
06/23CHUGAI PHARMACEUTICAL : Presentation
PU
06/23Galderma Announces Topline Results of OLYMPIA 2 Study Evaluating Nemolizumab in Prurigo..
AQ
06/20Roche Unit's Hemlibra Receives Japanese Nod for Additional Indication of Acquired Hemop..
MT
06/20Roche's Chugai, Zenyaku Kogyo Win Japanese Nod For Rituxan Drug Against Neuromyelitis O..
MT
06/20Roche's Chugai Pharmaceutical Wins Japanese Regulatory Nod For Changes To Leukemia, Ova..
MT
06/20CHUGAI PHARMACEUTICAL : Obtains Regulatory Approval for Hemlibra for Additional Indication..
PU
06/20CHUGAI PHARMACEUTICAL : Obtains Partial Change Approval for Neutrogin and Avastin Based on..
PU
06/20CHUGAI PHARMACEUTICAL : Anti-CD20 Monoclonal Antibody Rituxan Approved for the Prevention ..
PU
06/10Japan Index Trades Steadily in Red; Round One Shares Gain 9% as May Sales Exceed Pre-Pa..
MT
06/10Chugai Appeals Tokyo Court's Dismissal of Patent Infringement Lawsuit Against Sawai, Ni..
MT
06/09CHUGAI PHARMACEUTICAL : Notice of Filing an Appeal in Patent Infringement Lawsuit concerni..
PU
06/08Chugai Receives DX Grand Prix 2022 Awards in Digital Transformation Stocks (DX Stocks) ..
AQ
06/07Chugai Supports the Japan Climate Initiative's Calling to Raise Renewable Energy Target
AQ
More news
News in other languages on CHUGAI PHARMACEUTICAL CO., LTD
06/20L'Hemlibra de Roche reçoit l'approbation du Japon pour une indication supplémentaire de..
06/20Chugai et Zenyaku Kogyo (Roche) obtiennent le feu vert japonais pour le médicament Ritu..
06/20Chugai Pharmaceutical, filiale de Roche, obtient le feu vert des autorités japonaises p..
06/20ROCHE : extension d'indication pour l'Hemlibra (hémophilie) au Japon
06/20Roche-Tochter Chugai erhält Zulassungserweiterung für Blutermittel Hemlibra
More news
Analyst Recommendations on CHUGAI PHARMACEUTICAL CO., LTD
More recommendations
Chart CHUGAI PHARMACEUTICAL CO., LTD
Duration : Period :
Chugai Pharmaceutical Co., Ltd Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CHUGAI PHARMACEUTICAL CO., LTD
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 13
Last Close Price 3 624,00 JPY
Average target price 4 577,69 JPY
Spread / Average Target 26,3%
EPS Revisions
Managers and Directors
Tatsuro Kosaka Manager-Pharmaceutical Business Strategy Office
Osamu Okuda Manager-Life Cycle Management II
Itagaki Toshiaki CFO, Manager-Information Technology & Accounting
Hisafumi Okabe Senior Executive Officer & Head-Research
Junichi Nezu Executive Officer, GM-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
CHUGAI PHARMACEUTICAL CO., LTD-4.39%43 255
JOHNSON & JOHNSON4.94%468 758
ELI LILLY AND COMPANY17.55%294 514
PFIZER, INC.-11.41%289 747
ABBVIE INC.13.69%272 011
ROCHE HOLDING AG-15.85%269 131